It is personalized, well tolerated, and rooted in regenerative medicine
Patients who discontinue GLP-1 medications should work with healthcare providers on sustainable weight maintenance strategies
Phase 3 starts Q1 2026 Phase 3 GLP-1/Amylin VK2735 Viking Therapeutics Dual GLP-1/GIP agonist
[172] A 2025 observational study reported a modest increased risk of a serious eye condition in people with diabetes taking glucagon-like peptide-1 (GLP-1) receptor agonists
For example, erythematous patches, papules, and plaques have been reported (with a median onset of 2 months) in an estrogen- and progesterone-receptor-positive BC patient receiving anastrozole ( Given the confirmed association between dermatologic AEs and AIs such as anastrozole, exemestane, and letrozole, it is essential to clarify the relationship between specific AI agents and dermatologic AEs
But lets talk real talk: sometimes your body needs a minute to get with the program